Company / Total Debt
Sarepta Therapeutics Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$140.5M
FY2025
5-year range
$140.5M / $1.5B
FY2021-FY2025
Trend
-87.6%
vs FY2024
Sector context
#49 of 83
Health Care
What the data says
At $141M, Sarepta Therapeutics's total debt ranks #35 of 83 in the Health Care sector. Total Debt has declined for 3 consecutive years, from $1.5B in FY2022 to $141M in FY2025.
Based on SEC 10-K filings.
$141M in FY2025 with a 3-year CAGR of -55.0%.
Improved from $1.2B to $141M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -55.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#35 of 83 in Health CareTop 41% of 83This company $140.5M Sector average $6.2B
▼
-97.7% below sector average
Key checks
Key Insights
- Sarepta Therapeutics's total debt has declined for 3 consecutive years.
- 3-year CAGR of -55.0%, indicating a declining trend.
- In FY2025, total debt decreased 87.6% year-over-year.
- Ranks #49 out of 83 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -0.70 (distress zone, below 1.8 threshold)
- Negative profit margin: -11.3%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $140.5M | -87.6% |
| FY2024 | $1.1B | -8.1% |
| FY2023 | $1.2B | -19.8% |
| FY2022 | $1.5B | +174.0% |
| FY2021 | $563.7M | - |
| FY2020 | - | - |
| FY2019 | - | - |
| FY2018 | $420.6M | -2.4% |
| FY2017 | $431.1M | +2339.7% |
| FY2016 | $17.7M | -34.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026